FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Syndax Pharma Filing NDA for Revumenib

[ Price : $8.95]

Syndax Pharmaceuticals plans an NDA submission by year end for revumenib, a first-in-class menin inhibitor for treating patients w...

Patient Experience Data Stakeholder Comments

[ Price : $8.95]

Federal Register notice: FDA posts a summary of the comments received for the Methodological Challenges Related to Patient Experie...

Supreme Court Agrees to Hear Mifepristone Case

[ Price : $8.95]

The U.S. Supreme Court agrees to hear arguments in an appeal of the 5th Circuit Court of Appeals decision that places restrictions...

New Genetic Metabolic Disease Treatment A/C

[ Price : $8.95]

FDA says it is creating a nine-member Genetic Metabolic Diseases Advisory Committee.

Strengthen Botox Safety Warning: Public Citizen

[ Price : $8.95]

Public Citizen calls on FDA to strengthen the Botox Boxed Warning to highlight the risk of systemic iatrogenic botulism and relate...

Advanced Manufacturing Technologies Guidance

[ Price : $8.95]

FDA publishes a draft guidance on the Advanced Manufacturing Technologies Designation Program and its benefits for drug developmen...

Dolor Tech Settles Over Migraine Device

[ Price : $8.95]

Utah-based medical device company Dolor Technologies settles False Claims Act charges with the federal government over a device it...

Peptide Clinical Pharmacology Guidance

[ Price : $8.95]

FDA publishes a draft guidance with clinical pharmacology considerations to assist industry in developing peptide drug products.

Risk-Based Approach to Therapeutic Protein DDI

[ Price : $8.95]

CDER Office of Clinical Pharmacology policy lead Qin Sun uses a podcast to explain the agencys risk-based approach to evaluating d...

CDISC Study Tabulation Model Version 3.4

[ Price : $8.95]

Federal Register notice: CDER and CBER announce that support begins for version 2.0 of the Clinical Data Interchange Standards Con...